Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2022

04-10-2021 | Breast Cancer | Original Article

The effect of exercise on disease-free survival and overall survival in patients with breast cancer

Authors: Nadiye Akdeniz, Muhammet Ali Kaplan, Mehmet Küçüköner, Zuhat Urakçı, Şahin Laçin, Emre Hüsnü Ceylan, Abdurrahman Işıkdoğan

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2022

Login to get access

Abstract

Background

Positive effects of exercise in cancer patients have been reported.

Aim

To investigate whether intensity, duration, and timing of exercise affect disease relapse and mortality risk in patients with breast cancer (BC).

Methods

Patients with local or locally advanced stages of BC between January 2018 and January 2020 were recruited in the study. Sociodemographic and clinicopathological characteristics of patients were recorded. Exercise evaluation was performed by preparing a questionnaire and asking the patients face-to-face questions in the outpatient clinic.

Results

Risk of relapse was 58% lower in patients who exercised than inactive patients (p = 0.004). Patients who exercised for 2 to 5 days per week had a 63% lower relapse risk than inactive patients (p = 0.010). Risk of relapse was 66% lower in the patients who exercised for less than 1 h or 3 metabolic equivalent of task (MET)-hours per week when compared to inactive patients (p = 0.037). Similarly, relapse risk was 62% lower in patients who exercised between 1 to 3 h or 3 to 8.9 MET-hours per week than inactive patients (p = 0.026). Mortality risk was lower in patients who exercised than patients who did not (p = 0.027). A significantly decreased mortality risk was found in both groups that included patients who exercised for 1 to 5 days per week and patients who exercised for less than 3 h or 9 MET-hours per week when compared to inactive patients.

Conclusion

Exercise was associated with decreased relapse and mortality rates in patients with BC. Therefore, exercise should be recommended to BC patients as a significant component of the treatment.
Literature
4.
11.
go back to reference Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304 Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://​doi.​org/​10.​1093/​annonc/​mdr304
Metadata
Title
The effect of exercise on disease-free survival and overall survival in patients with breast cancer
Authors
Nadiye Akdeniz
Muhammet Ali Kaplan
Mehmet Küçüköner
Zuhat Urakçı
Şahin Laçin
Emre Hüsnü Ceylan
Abdurrahman Işıkdoğan
Publication date
04-10-2021
Publisher
Springer International Publishing
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2022
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-021-02785-y

Other articles of this Issue 4/2022

Irish Journal of Medical Science (1971 -) 4/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine